Ipsen Press Releases | Latest News & Updates

Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

– 18 November 2024

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in…

– 15 November 2024

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with…

– 23 October 2024

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its…

– 23 September 2024

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare…

– 20 September 2024

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary…

– 10 June 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…

Explore more press releases

Filter

Topics

Period

Filter by

recent search

Reset

Showing: 1 – 05 of 206 Press Releases

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Press Release Icon  –  18 November 2024

18 November 2024

Download
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label…


Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Press Release Icon  –  15 November 2024

15 November 2024

Download
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association for…


Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
Press Release Icon  –  23 October 2024

23 October 2024

Download
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

PARIS, FRANCE, 23 October 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024.


Ipsen receives its second Shingo Prize for operational excellence
Press Release Icon  –  14 October 2024

14 October 2024

Download
Ipsen receives its second Shingo Prize for operational excellence

PARIS, FRANCE, 14 October 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Dublin, Ireland production site has received the Shingo Prize for operational excellence. This is Ipsen’s second Shingo Prize, with its site in Signes, France, receiving…


Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
Press Release Icon  –  23 September 2024

23 September 2024

Download
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

PARIS, FRANCE, 23 September, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission has approved Kayfanda® (odevixibat) under exceptional circumstances for the treatment of cholestatic pruritus in Alagille Syndrome (ALGS) in patients aged 6 months or older….


Your dedicated contacts

Stay updated